



Development and Validation of a Nomogram for Differentiating Combined Hepatocellular Cholangiocarcinoma From Intrahepatic Cholangiocarcinoma

Tao Wang^{1†}, Wanxiang Wang^{2†}, Jinfu Zhang¹, Xianwei Yang¹, Shu Shen¹

OPEN ACCESS

Edited by:

and Wentao Wang^{1*}

Alessandro Vitale, University Hospital of Padua, Italy

Reviewed by:

Eliza Wright Beal, The Ohio State University Wexner Medical Center and James Cancer Hospital, United States Benedetto Ielpo, Hospital del Mar, Parc de Salut Mar, Spain

*Correspondence:

Wentao Wang wwtdoctor02@163.com

[†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Surgical Oncology, a section of the journal Frontiers in Oncology

Received: 24 August 2020 Accepted: 04 November 2020 Published: 09 December 2020

Citation:

Wang T, Wang W, Zhang J, Yang X, Shen S and Wang W (2020) Development and Validation of a Nomogram for Differentiating Combined Hepatocellular Cholangiocarcinoma From Intrahepatic Cholangiocarcinoma. Front. Oncol. 10:598433. doi: 10.3389/fonc.2020.598433 ¹ Department of Liver Surgery and Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, China, ² Department of Hepatobiliary, Pancreatic, and Splenic Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China

Objectives: To establish a nomogram based on preoperative laboratory study variables using least absolute shrinkage and selection operator (LASSO) regression for differentiating combined hepatocellular cholangiocarcinoma (cHCC) from intrahepatic cholangiocarcinoma (iCCA).

Methods: We performed a retrospective analysis of iCCA and cHCC patients who underwent liver resection. Blood signatures were established using LASSO regression, and then, the clinical risk factors based on the multivariate logistic regression and blood signatures were combined to establish a nomogram for a differential preoperative diagnosis between iCCA and cHCC. The differential accuracy ability of the nomogram was determined by Harrell's index (C-index) and decision curve analysis, and the results were validated using a validation set. Furthermore, patients were categorized into two groups according to the optimal cut-off values of the nomogram-based scores, and their survival differences were assessed using Kaplan-Meier curves.

Results: A total of 587 patients who underwent curative liver resection for iCCA or cHCC between January 2008 and December 2017 at West China Hospital were enrolled in this study. The cHCC score was based on the personalized levels of the seven laboratory study variables. On multivariate logistic analysis, the independent factors for distinguishing cHCC were age, sex, biliary duct stones, and portal hypertension, all of which were incorporated into the nomogram combined with the cHCC-score. The nomogram had a good discriminating capability, with a C-index of 0.796 (95% CI, 0.752–0.840). The calibration plot for distinguishing cHCC from iCCA showed optimal agreement between the nomogram prediction and actual observation in the training and validation sets. The decision curves indicated significant clinical usefulness.

1

Conclusion: The nomogram showed good accuracy for the differential diagnosis between iCCA and cHCC preoperatively, and therapeutic decisions would improve if it was applied in clinical practice.

Keywords: intrahepatic cholangiocarcinoma, combined hepatocellular cholangiocarcinoma, differential diagnosis, least absolute shrinkage and selection operator regression, nomogram

HIGHLIGHTS

cHCC is a rare, distinct entity different from iCCA. Using the clinical data obtained from West China Hospital, the authors discovered that the prognosis of the cHCC was significantly worse than that of iCCA. The novel validated nomogram presented herein is a tool that can effectively differentiate cHCC from iCCA preoperatively.

INTRODUCTION

Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer after hepatocellular carcinoma (1, 2). Combined hepatocellular cholangiocarcinoma (cHCC) is a rare malignant liver tumor containing components of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) (3, 4),accounting for 0.8%–14.3% of primary liver malignancies, with incidences widely varying among studies (5–7). Previous studies have classified cHCC and iCCA in the same category (8–10), but there is controversy about their clinical features and prognoses; for example, some studies have suggested that patients with cHCC have a poorer prognosis than those with iCCA (5, 11, 12), while other studies have reported the opposite conclusion (13).

An accurate differential diagnosis of cHCC and iCCA before surgery remains an important goal with prognostic significance because of differences in therapeutic strategies and prognoses between two; however, at present, the gold standard for cHCC diagnosis is still fine needle aspiration biopsy or a histopathological examination after surgery. With the development of radiological technology, there may be some features of imaging that imply cHCC; however, when cHCC has characteristics consistent with cholangiocarcinoma differentiation in variable proportion, cHCC is often easily misdiagnosed as iCCA (7, 14, 15). Thus, better preoperative noninvasive prediction models are needed to differentiate cHCC from iCCA. We retrospectively performed a comprehensive analysis of the clinicopathological characteristics and survival information of cHCC and iCCA patients in our single center. Furthermore, we established a feasible and straightforward simplified nomogram based on laboratory study variables selected by the least absolute shrinkage and selection operator (LASSO) regression analysis as well as other clinical risks obtained by multivariate logistic regression for the preoperative differential diagnosis between cHCC and iCCA. LASSO regression analysis was used to reduce high-dimensional data and choose the predictive factors in the differential diagnosis of cHCC and iCCA (16, 17).

METHODS

Patients and Study Design

This retrospective study was conducted on iCCA and cHCC patients who underwent curative liver resection between January 2008 and December 2017. Our selection criteria for patients in this study included the following (1) age \geq 18 years (2); patients who underwent R0 resection, defined as the absence of microscopic or gross residual disease, pathology of the resection margin is was confirmed to be negative, and after the organ or tissue directly invaded by the tumor was combined with resection, the surgical margin was also negative (3); contrast-enhanced CT of the abdomen and laboratory study were performed less than 1 week prior to surgery; and (4) detailed clinical characteristics. Our exclusion criteria for this study were as follows:(1) postoperative pathology confirmed hepatocellular carcinoma (HCC) and R1 excision or tumor margin was not specified in detail (2); the patient had a history of other extrahepatic malignancies; and (3) poor clinical data integrity. In this study, the whole set was randomly divided into two sets: the training set(n=412, 70%) and the validation set (n=175, 30%). The flowchart of the present study selection is shown in Figure 1 and the clinicopathologic characteristics of patients in the training and validation sets are listed in Table 1. This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of Sichuan University West China Hospital. Informed consent was obtained from all the patients.

Data Collection and Follow-Up

The clinical medical data of cHCC and iCCA patients who underwent curative liver resection were retrospectively collected from our hospital and included demographics, comorbid illnesses, portal hypertension, preoperative routine blood tests, biochemistry tests, tumor marker tests, tumor imaging data and survival information. In general, all patients who received curative liver resection were prospectively followed up through outpatient clinic visits or telephone calls at intervals of 2-3 months during the first year after the operation and 3-6 months thereafter. Chest CT examination, bone scintigraphy and PET-CT were performed when extrahepatic tumor recurrence was suspected. Oncological survival outcomes, including overall survival (OS) and recurrencefree survival (RFS), were collected until December 31, 2019. OS was defined as the interval between resection and death, or the period up to the last follow-up. RFS was defined as the interval from after surgery to tumor recurrence, including intrahepatic tumor recurrence and extrahepatic metastasis, or the period up to the last observation endpoint.



Risk Factors for Presence of cHCC

Univariate logistic regression analysis was performed to estimate the impacts of demographics, comorbid illnesses and imaging features on distinguishing cHCC and iCCA in the training set. Stepwise multivariate logistic regression analysis was further performed to screen for independent risk factors at a significant level. The LASSO logistic regression model was used to build a prognostic classifier, which integrated all types of laboratory study variables that can be obtained before surgery, to differentiate iCCA from cHCC in the training set. Using the coefficients derived from the LASSO logistic regression models, we then constructed a formula to calculate a score for each patient. We used the receiver operating characteristic (ROC) curve with calculations of the area under the curve (AUC) to determine the optimal cut-off value of the blood signature score. Restricted cubic spline (RCS) was used to evaluate the relationship between the blood signature score obtained by LASSO logistic regression and the outcome of distinguishing cHCC from iCCA.

Construction, Assessment, and Internal Validation of Nomograms

Laboratory study variables chosen by LASSO regression and the results of multivariate logistic regression were included in the model. All possible diagnostic factors are performed to construct a simplified nomogram for the differential diagnosis of iCCA and cHCC. The differential accuracy of the models was measured using the C-index, quantifying the level of agreement between the predicted probabilities and the actual possibility of having the event of interest, and the bootstrap estimate of slope shrinkage (18). The bootstrap resampling method was chosen for the internal validation of the predictive models' selecting 1000 repetitions. Decision curve analysis (DCA) was used to determine the clinical application value of the nomogram by evaluating the net benefit (19). Clinical impact curves were further drawn to evaluate the clinical impact of the nomogram to help understand its importance more intuitively (20).

Statistical Analysis

The Mann-Whitney U test was used to compare continuous variables between two patient groups. The chi-squared test and two-tailed Fisher's exact test were used for the comparison of categorical variables between two groups. Continuous variables are expressed as the medians and interquartile ranges(Q1-Q3), and categorical variables are expressed as the numbers and percentages. R version 4.0.0 (http://www.r-project.org/) was used for ROC curve analysis, RCS, LASSO logistic regression, nomogram generation, C-index assessment, calibration plot generation, and DCA. The rest of the analyses were conducted using SPSS statistical software version 25.0 (IBM Corporation, Armonk, NY). In all analyses, P < 0.05 was considered to indicate statistical significance.

TABLE 1 | Baseline characteristics of patients in intrahepatic cholangiocarcinoma (iCCA) and combined hepatocellular cholangiocarcinoma (cHCC).

	Variables	Patients						
iCCA group(-a28) iCRC group(n-13) iCRC group(n-13)<		Training set			Validation set			
App egent, makin (10A) Control (micro) (15(72) Control (micro) (15(72) Control (1000)57(63)55(63)50(7) Control (1000) Control (1000)55(73)50(7) Control (1000) Control (1000)50(7) Control (1000)60(7) Control (1000)<		iCCA group(n=280)	cHCC group(n=132)	P-value	iCCA group(n=118)	cHCC group(n=57)	P-value	
Gender (maler/female/, Portal lypedration, 1%) 15/129 10/02	Age (years), median (IQR)	57(48–64)	52(45–59)	0.005	58(50–64)	55(46.25–58)	0.004	
Portal Mysechension, n (%)	Gender (male/female),	151/129	105/27	< 0.001	55/63	50/7	< 0.001	
Yes 4Q(14.298), 24(08.271%) 32(20.23%), 27(2.46%) 13(11.02%), 10(08.848) 21(08.48%), 30(02.20%) 21(08.48%), 30(02.20%) 20(03.16%), 30(02.20%) 30(02.20%), 30(02.20%) 30(02.20%), 30(02.20%) 30(02.20%), 30(02.20%) 30(02.20%), 30(02.20%), 30(02.20%) 30(02.20%), 30(02.20%)	Portal hypertension, n (%)			0.003			< 0.001	
No24085.71%)97(7.3.4%)105(82.91%)38(85.16%)	Yes	40(14.29%)	35(26.52%)		13(11.02%)	21(36.84%)		
HBaAg positive, n (%)<	No	240(85.71%)	97(73.48%)		105(88.98%)	36(63.16%)		
YesB8(21.43%) NO102(70.55%) 27(20.45%)80(67.80%)17(29.87%) 100(78.78%)0.006Diabetes, n(%)0.700101(9.3%) 52(91.2%)65(9.8%) 52(91.2%)0.006Wes0.40(4.3%) 240(85.7%)115(87.1%)101(70.7%) 52(91.2%)52(91.2%) 52(91.2%)Biliary duct stones, n(%)2.40(85.7%)115(87.1%)0.0056.31(51.57.7%) 5.76(4.56.7.8%)5.76(4.56.7.8%)Wes0.23(83.9%)127(96.2%)0.0056.31(51.57.7%) 5.76(4.56.7.8%)5.76(4.56.7.8%)0.177 5.55(2.55.51.30.088Bealine latoratory investigationU1242.569.25.120.0153.3443.05.6.5.33.56(2.55.51.30.088PLT count x107/L, median (IOR)6.82(5.42-8.00)5.78(4.74-7.16)0.0056.31(61.57.7%)5.76(4.56-7.8%)0.011ALT LULL, median (IOR)0.80(2.42-8.00)5.78(4.72-7.5%)0.0078.2482.3738262-5.630.003QCG (ULL, median (IOR)0.80(2.42-8.00)3.52(2.57-5%)0.0080.0078.2482.3738262-5.630.001AST (ULL), median (IOR)18.459.93-77.1813.35(10.22-16%)0.0078.2482.47.313.38(50-20.4)0.148ALB (gL, median (IOR)18.459.93-77.611.02(1.4-12.9)0.0171.15(11-12.131.19(1.3-13)0.037THS, median (IOR)18.459.93-77.613.347(1.4-22.980.0011.02(1.9-6.16%)2.24(2.16-6.56)2.42(90.356.10%)0.001Cat LT (ULL, median (IOR)18.19(1.22-6.37)7.584(2.3-7.78)0.24(2.77-16.36)2.42(91.2	HBsAg positive, n (%)			< 0.001			< 0.001	
No1268.57%272.04%%80%17.129.82%9.00Obsetes, n(%)4.0(14.3%)11.129%, 11.129%, 11.0790.7%5.081.8%0.024Wes4.00(5.7%)11.067.3%10.7090.7%5.091.2%0.024Yes4.516.1%5.08.8%2.177.8%5.698.5%0.024Yes4.516.1%5.08.8%1.2706.2%5.78(4.56-7.8%0.177NeUC count x10 ¹ /L, median (0R)6.22(5.42-6.00)5.73(4.74-7.16)0.0055.78(4.56-7.8%)0.177NEUT count x10 ¹ /L, median (0R)6.22(5.42-6.10)0.0133.34(2.06-6.37)3.562(8.5-6.1)0.006PLT count x10 ¹ /L, median (0R)30.018-4733.262.26-78.1%0.0032.85(23-37)3.562(8.5-6.1)0.001ALT (UL), median (0R)30.018-473.32(6.12-8)0.0032.85(23-37)3.30(2.06-78.5%)-0.001GGT (UL), median (0R)18.46(9.08-17.18)3.36(10.2-180)0.0032.85(23-37)3.30(8.26-5.6)-0.001GGT (UL), median (0R)18.46(9.08-17.18)3.36(10.2-180)0.0011.179.38-14.730.3071.30(8.5-20-10)-0.016GGT (UL), median (0R)18.46(9.08-17.18)3.36(10.2-180)0.0011.179.38-14.730.3071.30(8.5-20-10)-0.016GGT (UL), median (0R)1.46(9.08-17.18)3.36(10.2-180)0.0011.109.13-1300.0071.16(11-130)0.0071.16(11-130)0.0071.16(11-120)1.2010.42-101.0011.001.440.0011.001.440.0011.001.440.0011.001.440.	Yes	88(31.43%)	105(79.55%)		38(32.20%)	40(70.18%)		
Diabetes, n (%) Control	No	192(68.57%)	27(20.45%)		80(67.80%)	17(29.82%)		
Yes 40(14.3%) 17(12.9%) 11(18/3%) 5(8.8%) Biliary duct stones, n (%) 240(85.7%) 115(87.1%) 107(90.7%) 52(91.2%) Piles 4.5(16.1%) 5(3.8%) 21(17.8%) 3(5.3%) No 230(83.3%) 127(86.2%) 97(82.2%) 54(94.7%) Baseline laboratory investigations 578(4.74-7.16) 0.016 6.31(5.15-7.76) 5.76(4.56-7.80) 0.177 NEUT count x10 ⁰ L, median (IQR) 4.24(3.33-5.55) 3.262.247-5.11) 0.018 3.49(3.06-6.37) 3.552.25-5.13 0.001 AST (UAL), median (IQR) 3.0(18-47) 33(25-49) 0.033 24.516-30 38(26.5-68) -0.001 AST (UAL), median (IQR) 3.0(18-47) 33(25-40) 0.38 26.822-75-136.5 61(38-120) 0.369 TILL (unolA), median (IQR) 3.45(9.33-17.18) 1.3.3(10.23-18.08) 0.970 11.1.6(38-14.73) 1.3.3(9.50-2.04) 0.148 ALS (QAL, median (IQR) 1.1.6(11.3-13) 0.017 1.3.3(9.50-2.04) 0.149 1.9.0(9.8-1.15) 0.016 FILG, unolAL, median (IQR)	Diabetes, n (%)			0.700			0.906	
No20(85.7%)115(87.1%)107(80.7%)52(81.2%)Biliary duct stones, n(%)5(3.8%)2.01010.024Yes2.35(8.3%)2.71(7.2%)3(5.3%)No2.35(8.3%)2.71(70.2%)3(5.2%)Baseline laboratory investigationsWBC count x10 ¹⁰ , median (IOR)6.62(5.42-8.00)5.78(4.74-7.16)0.0056.31(4.2-2.16)0.716PLT count x100 ¹ , median (IOR)6.62(5.42-8.00)5.78(4.74-7.16)0.0053.94(3.06-5.37)3.55(2.56-5.13)0.008PLT count x100 ¹ , median (IOR)183.5(122-19)142.5(99.25-192.5)0.01513.94(3.02-8.56)3.0007AST (UL), median (IOR)30(23-42)35.5(27-53)0.00728.5(27-73.8.5)13.36(0.23-10.08)0.970AST (UL), median (IOR)13.49(3.93-17.18)13.35(10.23-16.08)0.97011.7(19.38-14.73)13.3(9.02-0.4)0.148ALE (GUL), median (IOR)14.2(38.3-42.5)11.7(14.132)0.01711.5(11-12.3)1.0.0170.037TBL (unvolu), median (IOR)1.62(13.0-10.1)1.0011.04(0.86-1.5)0.001ALE (GUL), median (IOR)1.62(12.62-53)3.1.7(14.32-65.89)4.0013.24(21.65.80)1.001Ch19-9 level(UMI), median (IOR)7.8.19(9.28-861.3)3.1.7(14.32-65.89)4.0013.24(21.65.80)0.001Ch19-9 level(UMI), median (IOR)7.8.19(9.26-87)0.0015.7.3(13.37-403.98)2.3.49(13.64-47.61)0.001Tumor unberg1.02(0.67-10.8)1.02(15.5%)0.0015.24(2.16.85%) </td <td>Yes</td> <td>40(14.3%)</td> <td>17(12.9%)</td> <td></td> <td>11(9.3%)</td> <td>5(8.8%)</td> <td></td>	Yes	40(14.3%)	17(12.9%)		11(9.3%)	5(8.8%)		
Billary duct stones, n (%)	No	240(85.7%)	115(87.1%)		107(90.7%)	52(91.2%)		
Yes 45(16.1%) 5(2.8%) 21(17.8%) 36.3%) Baseline laboratory investigations 235(83.9%) 127(96.2%) 57(82.2%) 54(94.7%) Baseline laboratory investigations	Biliary duct stones, n (%)			< 0.001		· · · · ·	0.024	
No 235(83.9%) 127(96.2%) 97(82.2%) 54(94.7%) Baseline laboratory investion WBC count x10 ⁰ /L, median (UR) 6.62(5 42=8.00) 5.78(4.74-7.16) 0.005 6.31(5.15-7.76) 5.78(4.55e-7.80) 0.177 NEUT count x10 ⁰ /L, median (UR) 6.62(5 42=8.00) 5.78(4.74-7.16) 0.015 132(132=4.78) 139(93=1.55) 0.001 ALT (UA), median (UR) 030(18-47) 33(82-5-912.5) 0.015 132(132=4.78) 139(93=1.55) 0.001 AST (UA), median (UR) 030(23-42) 35(627-55) 0.033 28.262-75-138.55) 61(88-120) 0.380 OGG (UV), median (UCP) 13.45(93-74.51) 13.35(10.23-18.08) 0.970 11.71(3.43-45.93) 42.8(93.54.65.93) 43.8(93.54.65.00) 0.970 11.71(3.43-45.93) 42.8(93.54.65.00) 0.930 13.9(1.3-1.47.93) 0.0370 INR, median (UCP) 11.6(11.0-12.3) 12.0(11.4-12.9) 0.017 11.6(11.31.91.0.037 11.0(11.9-12.3) 12.0(11.4-12.93) 13.9(13.67.47.93) 0.38(13.67.47.93) 0.001 CA19-9 level(U/mL), median (UCP)	Yes	45(16,1%)	5(3.8%)		21(17.8%)	3(5.3%)		
Baseline laboratory investigations Extension Extension Extension WBC court x10 ⁹ L, median (IQR) 6.825(32–800) 5.78(4,74–7.16) 0.005 6.31(5,15–7.76) 5.76(4,56–7.80) 0.177 NBC court x10 ⁹ L, median (IQR) 183,5(12–219) 142,5(99,25–192.5) 0.018 3.94(3,06–5.37) 3.92(2,65–5.13) 0.001 ATL (U/L), median (IQR) 30(18–47) 33(22,65–30) 0.003 24,5(16–30) 38(2,65–5.65) <-0.001	No	235(83.9%)	127(96.2%)		97(82.2%)	54(94.7%)		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Baseline laboratory investigations	200(001070)	121 (001270)		01 (021270)	0 1(0 111 /0)		
NEUT count x10 ⁹ /L, median (ICR) 0.52(3.5.200) 0.0018 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.0-6.3.7) 0.018(3.3)(0.2-0.7) 0.018(3.3)(0.2-0.7) 0.018(3.3)(0.2-0.7) 0.018(3.3)(0.2-0.7) 0.018(3.3)(0.2-0.7) 0.018(3.3)(0.2-0.7) 0.018(3.3)(0.2-0.7) 0.018(3.3)(0.2-0.7) 0.016(3.3)(0.2-0.7) 0.011(3.3)(0.2-0.7) 0.011(3.3)(0.2-0.7) 0.011(3.3)(0.2-0.7) 0.011(3.3)(0.2-0.7) 0.033(3.2-46.6) 0.039 0.017(3.11.7) 0.031(3.2)(0.0-0.7) 0.011(3.13,0.0-0.2) 0.011(3.2)(1.1-1.2) 0.011(3.2)(1.1-1.2) 0.011(3.2)(1.1-1.2) 0.011(3.2)(1.1-1.2) 0.011(3.2)(1.1-1.2) 0.011(3.2)(1.1-1.2) 0.011(3.2)(1.1-1.2) 0.011(3.2)(1.1-1.2) 0.011(3.2)(1.1-1.2) 0.011(3.2)(1.1-1.2) 0.011(3.2)(1.1-1.2) 0.037 PT(s), median (IQF) 1.2(0.106.3) 1.12(1.1-2.13) 0.001 5.2(1.0-1.5) 0.021 5.2(1.0-1.5) <	WBC count $\times 10^9$ /L median (IOB)	6 62(5 42-8 00)	5 78(4 74-7 16)	0.005	6.31(5.15-7.76)	5 76(4 56-7 80)	0 177	
The Structure 0.0001 10(CR) 0.035(122-218.7) 0.015 0.034(02-218.7) 0.001 ALT (U/L), median (ICR) 30(18-47) 33(22-49) 0.033 24.5(16-66) 38(25.5-68) -0.001 AST (U/L), median (ICR) 30(23-42) 35.5(27-63) 0.007 25.5(23-67) 316(27-55.05) -0.001 GGT (U/L), median (ICR) 13.45(9.33-17.18) 13.3(5(12.23-18.06) 0.970 11.7(9.38-14.7.3) 13.3(9.50-20.4) 0.138 ALB (g/L), median (ICR) 12.45(9.7-43) 0.011 10.0(9.8-1.47.3) 13.3(9.50-20.4) 0.148 ALB (g/L), median (ICR) 12.45(9.7-47.1) 0.13.3(10.23-18.06) 0.970 11.7(9.38-14.7.3) 13.3(9.50-20.4) 0.148 INR, median (ICR) 11.6(11-0-12.3) 12.0(11.4-12.9) 0.011 11.0(10.8-1.47.3) 12.0(11.4-12.9) 0.011 1.0(0.8-1.16) 1.040.038-1.16) 0.001 AFP, ng/ml median (ICR) 3.18(2.26-5.37) 75.84(6.35-621) -0.001 3.24(2.16-5.68) 44.09(3.71-226.10) -0.011 Tumor size (cm), median (ICR) 7.13(12,77-8) 0.001 5.7(3.21-7.69) 0.048 6(10-5.9) 5.7(3.21-7.6) 0.001	NELIT count $\times 10^9$ /L median (IQR)	4 24(3 33-5 65)	3 62/2 87_5 11)	0.000	3.94(3.06-5.37)	3 55(2 85-5 13)	0.068	
PL1 could x losic_median (IQR) 103(12-22:15) 142.092.00 103(13-22:16-30) 103(13-22:16-30) 103(13-22:16-30) 0.001 ALT (U/L), median (IQR) 30(18-47) 33(22-49) 0.033 24.5(16-36) 38(225-56) -0.001 AST (U/L), median (IQR) 0.3423-42) 35.5(27-53) 0.007 28.5(23-37) 35.6(27.5-05.5) -0.001 GGT (U/L), median (IQR) 13.45(9.39-17.18) 13.35(10.23-18.08) 0.970 11.7(9.38-14.73) 13.3(9.50-20.4) 0.148 ALB (g/L), median (IQR) 11.6(11-0-12.3) 12.0(11-4-12.9) 0.017 11.5(11-12.13) 11.9(11.3-13) 0.037 FIRS, median (IQR) 1.1.6(11-0-12.3) 12.0(11-4-12.9) 0.011 1.0(0.95-1.06) 1.04(0.98-1.15) 0.001 AFP, ng/m median (IQR) 1.812.26-53.77 75.84(6.35-621) -0.001 3.242(1-6-5.68) 4.0(06.71-226.10) -0.001 CA19-9 level(U/mL), median (IQR) 78.16(9.28-661.35) 31.17(14.32-96.89) -0.001 57.13(13.77-439.98) 23.49(13.64-47.61) -0.001 Tumor unset (m), median (IQR) 78.16(9.28-661.35) 31.17(14.32-96.89)	DLT count x100/L, median (IQR)	4.24(0.00-0.00)	140 5(00 05 100 5)	0.015	120(120,010,75)	120/02 15 5)	0.000	
ALT (UL), median (UR) 30(12-47) 33(23-49) 0.033 24-3(10-36) 36(25-3-3) C0.001 GAT (UL), median (UR) 66(36-132.25) 71(41-135) 0.586 66(22.75-136.5) 61(38-120) 0.307 JBL (unol/L), median (UR) 13.45(9.93-74.51) 13.15(10.23-18.08) 0.970 11.7(9.38-14.73) 13.3(5.0-20.4) 0.148 ALB (g/L), median (UR) 11.6(11-0-12.3) 12.0(11.4-12.9) 0.017 11.5(11-12.13) 11.9(11.3-13) 0.037 INR, median (UR) 11.0(20.96-1.06) 0.5(1.01-1.13) 0.001 1.0(0.98-1.06) 1.0(0.98-1.16) 0.001 CA19-9 level(U/mL), median (UR) 78.19(19.28-661.35) 31.17(14.32-96.59) <0.001	ALT (U(L) median (IQD)	00(10,47)	142.3(99.23-192.3)	0.015	04 5(10, 20)	139(03-13.3)	-0.001	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	ACT (U/L), median (IQR)	30(18-47)	33(20-49)	0.033	24.3(10-30)	38(20.3-38)	<0.001	
GL1 (UDL), Median (UCH) bb(36-132.2b) 7.1(1-13b) 0.396 bb(22, 2-1-35, 5) b1(36-120) 0.390 TBL (LUNC), Median (UCR) 13.45(9.37-45, 1) 41.3(30, 33(10, 23-18, 08) 0.970 11.7(9, 38-14-73) 13.3(9, 50-24, 0) 0.148 ALB (g/L), median (UCR) 11.6(11, 0-12, 3) 12.0(11, 4-12, 9) 0.071 11.5(11-12, 13) 11.9(11, 3-13) 0.037 INR, median (UCR) 13.18(2, 26-5, 37) 75.84(6, 35-621) <0.001	AST (U/L), median (IQR)	30(23-42)	35.5(27-53)	0.007	28.5(23-37)	35(27.5-50.5)	< 0.001	
	GGT (U/L), median (IQR)	66(36-132.25)	71(41-135)	0.598	66(22.75-136.5)	61(38–120)	0.360	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	I BIL (umol/L), median (IQR)	13.45(9.93–17.18)	13.35(10.23–18.08)	0.970	11.7(9.38–14.73)	13.3(9.50–20.4)	0.148	
PT(s), median (IQR) 11.5(11.0-12.3) 12.0(11.4-12.9) 0.017 11.5(11-12.13) 11.9(11.3-13) 0.037 INR, median (IQR) 1.02(0.96-1.08) 1.05(1.01-1.13) 0.001 3.24(2.16-5.68) 44.09(3.71-226.10) <0.001	ALB (g/L), median (IQR)	42.5(39.7–45.1)	41.7(38.03–44.5)	0.274	42.7(40.28–45.93)	42.8(39.35–46.6)	0.958	
INR, median (IGR) 1.02(0.96-1.08) 1.05(1.01-1.13) 0.001 1.04(0.98-1.15) 0.001 AFP, ng/ml median (IQR) 3.18(2.26-5.37) 75.34(6.35-621) <0.001	PT(s), median (IQR)	11.6(11.0–12.3)	12.0(11.4–12.9)	0.017	11.5(11–12.13)	11.9(11.3–13)	0.037	
AFP, ng/ml median (IQP) 3.18(2.2e–5.37) 75.84(6.35–621) <0.001 3.24/2.16–5.68 44.09(3.71–226.10) <0.001 CA19-9 level(U/mL), median (IQP) 78.19(19.28–861.35) 31.17(14.32–95.89) <0.001 57.13(13.77–493.98) 23.49(13.64–47.61) <0.001 Tumor size (cm), median (range) 5.5(4.2–8) 5.5(3.7–7.8) 0.448 6(4.6–8.0) 5.3(3.1–7.05) 0.091 multiple 90(32.14%) 36(27.27%) 9(33.1%) 6(10.5%) 0.001 multiple 90(32.14%) 96(72.73%) 9(3(3.1%) 6(10.5%) 0.001 Tumor location -<0.001 0.002 0.004 16(159.9%) 96(72.73%) 24(23.7%) 33(3.1%) 6(10.5%) 0.001 Left lobe 116(41.43%) 28(21.21%) 46(39.0%) 21(68.8%) 0.002 0.002 0.002 Extern of liver resection, n(%) 0.013(36.64%) 24(21.82%) 0.028 0.021 0.021 Major 116(40.71%) 42(31.82%) 0.002 24(23.80%) 24(28.60%) 0.021 No 22(88.13%)<	INR, median (IQR)	1.02(0.96-1.08)	1.05(1.01–1.13)	0.001	1.0(0.95–1.06)	1.04(0.98–1.15)	0.001	
CA19-9 level(U/mL), median (IQR) 78.19(19.28–861.35) 31.17(14.32–95.89) <0.001	AFP, ng/ml median (IQR)	3.18(2.26–5.37)	75.84(6.35–621)	<0.001	3.24(2.16-5.68)	44.09(3.71-226.10)	< 0.001	
Tumor size (cm), median (range) 5.5(4.2-8) 5.5(3.7-7.8) 0.448 6(4.6-8.0) 5.3(3.1-7.05) 0.098 Tumor number (Multiple/solitary), 03(27.27%) 39(33.1%) 6(10.5%) 0.001 multiple 90(32.14%) 36(27.27%) 99(33.1%) 6(10.5%) 0.001 solitary 190(67.86%) 96(72.73%) 79(66.9%) 51(89.5%) 0.004 Left lobe 116(41.43%) 28(21.21%) 46(37.3%) 33(57.9%) 0.004 Bight lobe 103(36.79%) 24(63.64%) 44(37.3%) 33(57.9%) 0.024 Extent of liver resection, n(%) 00(68.18%) 28(23.7%) 3(5.34) 0.024 major 114(40.71%) 42(31.82%) 37(31.36%) 22(38.60%) 0.021 Yes 52(18.57%) 43(32.58%) 21(17.80%) 23(40.35%) 0.011 Yes 52(86.71%) 96(34.29%) 37(28.03%) 36(29.66%) 19(33.33%) 0.021 Yes 96(34.29%) 37(28.03%) 36(20.66%) 19(33.33%) 0.021 <td< td=""><td>CA19-9 level(U/mL), median (IQR)</td><td>78.19(19.28–861.35)</td><td>31.17(14.32–95.89)</td><td>< 0.001</td><td>57.13(13.77–493.98)</td><td>23.49(13.64–47.61)</td><td>< 0.001</td></td<>	CA19-9 level(U/mL), median (IQR)	78.19(19.28–861.35)	31.17(14.32–95.89)	< 0.001	57.13(13.77–493.98)	23.49(13.64–47.61)	< 0.001	
Tumor number (Multiple/solitary), 0.317 0.011 multiple 90(32.14%) 36(27.27%) 39(33.1%) 6(10.5%) solitary 190(67.86%) 96(72.73%) 79(66.9%) 51(89.5%) Tumor location 0.004 109(67.86%) 24(36.8%) 21(36.8%) 21(36.8%) Right lobe 116(41.43%) 28(21.21%) 46(39.0%) 21(36.8%) 3(3(57.9%) Both lobes 103(36.79%) 84(63.64%) 44(37.3%) 33(57.9%) 3(5.3%) Both lobes 103(36.79%) 84(63.64%) 48(3.84%) 3(5.140%) 3(5.9%) major 166(59.29%) 90(88.18%) 81(88.64%) 35(61.40%) 32(40.35%) minor 114(40.71%) 42(32.82%) 7(31.36%) 23(40.35%) 3(40.35%) Mol 228(81.43%) 89(67.42%) 97(82.20%) 34(59.65%) 3(33.33%) 666.65%) 3(33.33%) 666.67%) 3(33.33%) 38(65.67%) 3(33.33%) 38(66.7%) 3(32.40%) 38(66.7%) 3(32.41%) 3(32.41%) 3(32.41%) 3(32.41%) 3(32.41%) 3(33.33%) 38(66.67%) 3(33.33%) <	Tumor size (cm), median (range)	5.5(4.2-8)	5.5(3.7-7.8)	0.448	6(4.6-8.0)	5.3(3.1-7.05)	0.098	
multiple 90(32.14%) 36(27.27%) 39(33.1%) 6(10.5%) solitary 190(67.86%) 96(72.73%) 79(66.9%) 51(89.5%) Tumor location 0.001 0.001 Left lobe 116(41.43%) 28(21.21%) 46(39.0%) 33(57.9%) 33(57.9%) Bight lobe 103(36.79%) 84(63.64%) 44(37.3%) 33(57.9%) 35(5.3%) Extent of liver resection, n(%) 0.002 28(23.7%) 3(5.3%) 35(61.40%) major 166(59.29%) 90(68.18%) 81(86.64%) 22(38.60%) 36(4.05%) minor 114(40.71%) 42(31.82%) 0.7(31.36%) 22(38.60%) 0.002 MV, n (%) 0.002 0.002 0.001 0.001 0.002 0.001	Tumor number (Multiple/solitary),			0.317			0.001	
solitary 190(67.86%) 96(72.73%) 79(66.9%) 51(89.5%) Tume location <.0.001 Left lobe 116(14.13%) 28(21.21%) 46(39.0%) 21(36.8%) Bight lobe 103(36.79%) 84(63.64%) 44(37.3%) 33(57.9%) Both lobes 61(21.78%) 20(15.15%) 28(23.7%) 3(5.3%) Exter of liver resection, n(%) 0.082 37(31.36%) 23(63.0%) major 166(59.29%) 90(81.8%) 31(86.64%) 35(61.40%) minor 114(40.71%) 42(31.82%) 37(31.36%) 23(40.35%) MV, n (%) 0.002 0.002 0.001 Yes 52(18.57%) 43(32.58%) 21(17.80%) 23(40.35%) No 28(81.43%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) No 238(80%) 108(81.82%) 27(17.80%) 38(66.67%) No 238(80%) 108(81.82%) 27(17.80%) 38(66.67%) <t< td=""><td>multiple</td><td>90(32.14%)</td><td>36(27.27%)</td><td></td><td>39(33.1%)</td><td>6(10.5%)</td><td></td></t<>	multiple	90(32.14%)	36(27.27%)		39(33.1%)	6(10.5%)		
Tumor location <0.001 0.004 Left lobe 116(41.43%) 28(21.21%) 46(39.0%) 21(36.8%) Piight lobe 103(36.79%) 84(63.64%) 44(37.3%) 33(57.9%) Both lobes 61(21.78%) 20(51.55%) 28(23.7%) 33(57.9%) Extent of liver resection, n(%) 0.082 0.342 major 166(59.29%) 90(68.18%) 81(68.64%) 35(61.40%) minor 114(40.71%) 42(31.82%) 37(31.36%) 22(38.60%) MVI, n(%) 0.002 0.002 0.001 Yes 52(18.57%) 43(32.58%) 21(17.80%) 23(40.35%) No 228(81.43%) 89(67.42%) 97(82.20%) 34(59.65%) Macroscopic vascular invasion, n(%) 0.205 0.622 0.622 Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(15.71%) 24(18.18%) 21(17.80%) 13(22.81%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) No	solitary	190(67.86%)	96(72.73%)		79(66.9%)	51(89.5%)		
Left lobe 116(41.43%) 28(21.21%) 46(39.0%) 21(36.8%) Right lobe 103(36.79%) 84(63.64%) 44(37.3%) 33(57.9%) Both lobes 61(21.78%) 20(15.15%) 28(23.7%) 33(51.9%) Extent of liver resection, n(%) 0.082 0.032 0.342 major 166(59.29%) 90(68.18%) 31(68.64%) 35(61.40%) minor 114(40.71%) 42(31.82%) 37(31.36%) 22(38.60%) MVI, n (%) 52(18.57%) 43(32.58%) 21(17.80%) 23(40.35%) No 28(81.43%) 89(67.42%) 97(82.00%) 34(59.65%) 0.001 Yes 96(34.29%) 37(28.03%) 23(29.66%) 19(33.33%) 0 No 184(65.71%) 24(18.18%) 25(17.87%) 38(20.66%) 0.413 Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) 0 No 184(65.71%) 24(18.18%) 21(17.80%) 13(22.81%) 0.432 No 238(850%) 108(81.82%) <td>Tumor location</td> <td>, , , , , , , , , , , , , , , , , , ,</td> <td>, , , , , , , , , , , , , , , , , , ,</td> <td>< 0.001</td> <td></td> <td></td> <td>0.004</td>	Tumor location	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,	< 0.001			0.004	
Right lobe 103(36,79%) 84(63,64%) 44(37.3%) 33(57.9%) Both lobes 61(21.78%) 20(15.15%) 28(23.7%) 3(5.3%) Extent of liver resection, n(%) 0.082 0.342 major 166(59.29%) 90(68.18%) 81(68.64%) 35(61.40%) minor 114(40.71%) 42(31.82%) 37(31.36%) 22(38.0%) MVI, n (%) 0.002 0.001 34(59.65%) 0.001 Yes 52(18.57%) 43(32.58%) 21(17.80%) 23(40.35%) No 228(81.43%) 89(67.42%) 97(82.20%) 34(59.65%) Macroscopic vascular invasion, n(%) 0.205 0.622 Yes 96(34.29%) 37(28.03%) 35(70.34%) 38(66.7%) No 28(81.43%) 95(71.97%) 63(70.34%) 38(66.7%) Satellite nodules, n(%) 0.411 0.432 0.422.81%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) Vers 42(15%) 24(18.18%) 210(7.18%) 13(22.81%) <t< td=""><td>Left lobe</td><td>116(41,43%)</td><td>28(21,21%)</td><td></td><td>46(39.0%)</td><td>21(36.8%)</td><td></td></t<>	Left lobe	116(41,43%)	28(21,21%)		46(39.0%)	21(36.8%)		
Both lobes 61(21.78%) 20(15.15%) 28(23.7%) 3(5.3%) Extent of liver resection, n(%) 0.082 0.342 major 166(59.29%) 90(68.18%) 81(68.64%) 35(61.40%) minor 114(40.71%) 42(31.82%) 37(31.36%) 22(38.60%) MVI, n (%) 0.002 0.001 Yes 52(18.57%) 43(32.58%) 21(17.80%) 23(40.35%) No 228(81.43%) 89(67.42%) 97(82.20%) 34(59.65%) Macroscopic vascular invasion, n(%) 0.205 0.622 0.622 Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) Yes 42(15%) 24(18.18%) 21(17.80%) 13(22.81%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) <td< td=""><td>Right lobe</td><td>103(36,79%)</td><td>84(63.64%)</td><td></td><td>44(37.3%)</td><td>33(57.9%)</td><td></td></td<>	Right lobe	103(36,79%)	84(63.64%)		44(37.3%)	33(57.9%)		
Extent of liver resection, n(%) 0.002 0.342 major 166(59.29%) 90(68.18%) 81(68.64%) 35(61.40%) minor 114(40.71%) 42(31.82%) 37(31.36%) 22(38.60%) MVI, n (%) 0.002 0.001 90(68.18%) 21(17.80%) 23(40.35%) No 228(81.43%) 89(67.42%) 97(82.20%) 34(59.65%) 0.622 Macroscopic vascular invasion, n(%) 0.205 0.622 0.622 Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) Satellite nodules, n(%) 0.411 0.432 Yes 42(15%) 24(18.18%) 21(17.80%) 13(22.81%) No 238(850%) 108(81.82%) 0.754 0.027 Yes 42(15%) 24(15.18%) 32(27.12%) 7(12.28%) No 238(850%) 108(81.82%) 0.024 0.027 Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%) </td <td>Both lobes</td> <td>61(21,78%)</td> <td>20(15.15%)</td> <td></td> <td>28(23.7%)</td> <td>3(5.3%)</td> <td></td>	Both lobes	61(21,78%)	20(15.15%)		28(23.7%)	3(5.3%)		
major 166(59.29%) 90(68.18%) 81(68.64%) 35(61.40%) minor 114(40.71%) 42(31.82%) 37(31.36%) 22(38.60%) MVI, n (%) 0.002 0.001 Yes 52(18.57%) 43(32.58%) 21(17.80%) 23(40.35%) No 228(81.43%) 89(67.42%) 97(82.20%) 34(59.65%) Macroscopic vascular invasion, n(%) 0.205 0.622 Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) Satellite nodules, n(%) 0.411 0.432 Yes 96(34.29%) 24(18.18%) 21(17.80%) 13(22.81%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) Yes 42(15%) 24(18.18%) 21(17.80%) 13(22.81%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) Lymph node metastasis, n (%) 0.024 0.027 0.027 Present 70(25%) <td2< td=""><td>Extent of liver resection, n(%)</td><td>01(2111070)</td><td>20(1011070)</td><td>0.082</td><td>20(2011 /0)</td><td>0(01070)</td><td>0.342</td></td2<>	Extent of liver resection, n(%)	01(2111070)	20(1011070)	0.082	20(2011 /0)	0(01070)	0.342	
minor 114(40.71%) 42(31.82%) 37(31.36%) 22(8.60%) MVI, n (%) 0.002 0.001 Yes 52(18.57%) 43(32.58%) 21(17.80%) 23(40.35%) No 228(81.43%) 89(67.42%) 97(82.20%) 34(59.65%) Macroscopic vascular invasion, n(%) 0.205 0.622 Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) Yes 96(34.29%) 37(28.03%) 37(81.20%) 36(66.67%) No 238(850%) 108(81.82%) 9(83.20%) 13(22.81%) Lymph node metastasis, n (%) 0.024 9(712.88%) 0.027 Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%)	major	166(59,29%)	90(68 18%)	01002	81(68 64%)	35(61 40%)	01012	
Mile Page 100 (2000) Page 100 (2	minor	114(40 71%)	42(31 82%)		37(31.36%)	22(38,60%)		
Yes 52(18.57%) 43(32.58%) 21(17.80%) 23(40.35%) No 228(81.43%) 89(67.42%) 97(82.20%) 34(59.65%) Macroscopic vascular invasion, n(%) 0.205 0.622 Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) Satellite nodules, n(%) 0.411 0.432 Yes 42(15%) 24(18.18%) 21(17.80%) 13(22.81%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) Lymph node metastasis, n (%) 0.024 0.027 0.027 Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%) Absent 210(75%) 112(84.85%) 86(72.88%) 50(87.72%) Tumor encapsulation, n (%), 0.759 0.028 0.088 incomplete 153(54.64%) 70(53.03%) 74(62.71%) 28(49.12%)	MVI n (%)	114(40.1170)	42(01.0270)	0.002	07(01:0070)	22(00:0070)	0.001	
Tes 32(10.37 %) 40(32.30 %) 21(17.80 %) 22(40.33 %) No 228(81.43%) 89(67.42%) 97(82.20%) 34(59.65%) Macroscopic vascular invasion, n(%) 0.205 0.622 Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) Satellite nodules, n(%) 0.411 0.432 Yes 42(15%) 24(18.18%) 21(17.80%) 13(22.81%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) Lymph node metastasis, n (%) 0.024 0.027 0.027 Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%) Absent 210(75%) 112(84.85%) 86(72.88%) 50(87.72%) Tumor encapsulation, n (%), 0.759 0.088 incomplete 153(54.64%) 70(53.03%) 74(62.71%) 28(49.12%)	Voc	50(19 570/)	12(22 58%)	0.002	21/17 80%)	22(10 25%)	0.001	
No 228(81.43%) 89(81.42%) 97(82.20%) 84(85.05%) Macroscopic vascular invasion, n(%) 0.205 0.622 Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) Satellite nodules, n(%) 0.411 0.432 Yes 42(15%) 24(18.18%) 21(17.80%) 13(22.81%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) Lymph node metastasis, n (%) 0.024 0.027 Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%) Absent 210(75%) 112(84.85%) 86(72.88%) 50(87.72%) Tumor encapsulation, n (%), 0.759 0.088 incomplete 153(54.64%) 70(53.03%) 74(62.71%) 28(49.12%)	No	000/01 /00/)	40(02.0070)		21(17.0070)	20(40.0070)		
Macroscopic vascular invasion, n(%) 0.205 0.622 Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) Satellite nodules, n(%) 0.411 0.432 Yes 42(15%) 24(18.18%) 21(17.80%) 13(22.81%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) Lymph node metastasis, n (%) 0.024 0.027 Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%) Absent 210(75%) 112(84.85%) 86(72.88%) 50(87.72%) Tumor encapsulation, n (%), 0.759 0.088 incomplete 153(54.64%) 70(53.03%) 74(62.71%) 28(49.12%)		220(01.43%)	09(07.4270)	0.005	97(02.2070)	34(39.03%)	0.000	
Yes 96(34.29%) 37(28.03%) 35(29.66%) 19(33.33%) No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) Satellite nodules, n(%) 0.411 0.432 Yes 42(15%) 24(18.18%) 21(17.80%) 13(22.81%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) Lymph node metastasis, n (%) 0.024 0.027 Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%) Absent 210(75%) 112(84.85%) 86(72.88%) 50(87.72%) Tumor encapsulation, n (%), incomplete 0.759 0.088	Macroscopic vascular invasion, n(%)	00(04.000()	07(00,000()	0.205	05(00,000()	10/00 000/)	0.622	
No 184(65.71%) 95(71.97%) 83(70.34%) 38(66.67%) Satellite nodules, n(%) 0.411 0.432 Yes 42(15%) 24(18.18%) 21(17.80%) 13(22.81%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) Lymph node metastasis, n (%) 0.024 0.027 0.027 Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%) Absent 210(75%) 112(84.85%) 86(72.88%) 50(87.72%) Tumor encapsulation, n (%), 0.759 0.088 incomplete 153(54.64%) 70(53.03%) 74(62.71%) 28(49.12%)	Yes	96(34.29%)	37(28.03%)		35(29.66%)	19(33.33%)		
Satellite nodules, n(%) 0.411 0.432 Yes 42(15%) 24(18.18%) 21(17.80%) 13(22.81%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) Lymph node metastasis, n (%) 0.024 0.027 Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%) Absent 210(75%) 112(84.85%) 86(72.88%) 50(87.72%) Tumor encapsulation, n (%), 0.759 0.088 incomplete 153(54.64%) 70(53.03%) 74(62.71%) 28(49.12%)	No	184(65.71%)	95(71.97%)		83(70.34%)	38(66.67%)		
Yes 42(15%) 24(18.18%) 21(17.80%) 13(22.81%) No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) Lymph node metastasis, n (%) 0.024 0.027 Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%) Absent 210(75%) 112(84.85%) 86(72.88%) 50(87.72%) Tumor encapsulation, n (%), incomplete 0.759 0.088	Satellite nodules, n(%)			0.411			0.432	
No 238(850%) 108(81.82%) 97(83.20%) 44(77.19%) Lymph node metastasis, n (%) 0.024 0.027 Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%) Absent 210(75%) 112(84.85%) 86(72.88%) 50(87.72%) Tumor encapsulation, n (%), incomplete 0.759 0.088	Yes	42(15%)	24(18.18%)		21(17.80%)	13(22.81%)		
Lymph node metastasis, n (%) 0.024 0.027 Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%) Absent 210(75%) 112(84.85%) 86(72.88%) 50(87.72%) Tumor encapsulation, n (%), incomplete 0.759 0.088	No	238(850%)	108(81.82%)		97(83.20%)	44(77.19%)		
Present 70(25%) 20(15.15%) 32(27.12%) 7(12.28%) Absent 210(75%) 112(84.85%) 86(72.88%) 50(87.72%) Tumor encapsulation, n (%), incomplete 0.759 0.088 153(54.64%) 70(53.03%) 74(62.71%) 28(49.12%)	Lymph node metastasis, n (%)			0.024			0.027	
Absent 210(75%) 112(84.85%) 86(72.88%) 50(87.72%) Tumor encapsulation, n (%), incomplete 0.759 0.088 153(54.64%) 70(53.03%) 74(62.71%) 28(49.12%)	Present	70(25%)	20(15.15%)		32(27.12%)	7(12.28%)		
Tumor encapsulation, n (%), incomplete 0.759 0.088 153(54.64%) 70(53.03%) 74(62.71%) 28(49.12%)	Absent	210(75%)	112(84.85%)		86(72.88%)	50(87.72%)		
incomplete 153(54.64%) 70(53.03%) 74(62.71%) 28(49.12%)	Tumor encapsulation, n (%),			0.759			0.088	
	incomplete	153(54.64%)	70(53.03%)		74(62.71%)	28(49.12%)		
complete 127(45.36%) 62(46.97%) 44(37.29%) 29(50.88%)	complete	127(45.36%)	62(46.97%)		44(37.29%)	29(50.88%)		

HBsAg, hepatitis B surface antigen; WBC, white blood cell; NEU, neutrophil; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate transaminase; GGT, γ -glutamyl transferase; TBIL, total bilirubin; ALB, albumin; PT, Prothrombin time; INR, international normalized ratio; AFP, alpha fetoprotein; CA19-9, carbohydrate antigen 19-9; MVI, microvascular invasion.

RESULTS

Clinical Characteristics of the Study Patients

A total of 587 patients (361 men, 226 women) who underwent curative liver resection for iCCA and cHCC between January 2008 and December 2017 at West China Hospital were enrolled in this study. All iCCA and cHCC patients were followed up after initial treatment until December 2019. In the training set, a total of 412 patients, including 132 cHCC patients and 280 iCCA patients. For the validation set, 175 consecutive patients were studied, consisting of 57 cHCC patients and 118 iCCA patients. There were more males in the cHCC group than in the iCCA group. Portal hypertension and HBsAg positivity were more common in patients with cHCC. However, microvascular invasion (MVI) and lymph node metastasis were more common in the iCCA group. Patients with cHCC were younger and had higher serum alpha-fetoprotein (AFP) levels and lower serum CA19-9 levels than patients with iCCA. The baseline clinicopathologic characteristics of the patients are listed in Supplementary Table 1. Among the entire set, the median overall survival (OS) of 189 patients with cHCC was 16.2 months and that of the 398 patients with iCCA was 18.6 months. The patients in the cHCC group had poorer OS and RFS than those in the iCCA group. The 1-, 3-, and 5-year OS rates were 78.3%, 12.2%, and 3.2%, respectively, in patients with cHCC and 70.1%, 23.1%, and 7.8%, respectively, in patients with iCCA (Figure 2).

Constructing a Simplified Prediction Model and Internal Validation

To distinguish between cHCC and iCCA well before surgery and guide clinical decision making, univariate logistic regression analysis was performed to estimate the impacts of demographics, comorbid illnesses, and imaging features on the differential diagnosis of cHCC and iCCA in the training set. According to univariable logistic regression analysis, age, sex, biliary duct stones, and portal hypertension were associated with the possibility of cHCC diagnosis. Stepwise multivariate logistic regression analysis was further performed to identify significant independent risk factors. The multivariate analyses revealed that age (≥55 vs. <55 years, OR, 0.568, 95%CI, 0.366-0.882, P=0.012), sex (female vs. male, OR, 0.354, 95%CI, 0.215-0.582, P<0.001), biliary duct stones (yes vs. no, OR, 0.274, 95% CI, 0.103-0.729, P=0.010), and portal hypertension (present vs. absent, OR, 1.816, 95% CI, 1.066-3.095, P=0.028) were independent risk factors for distinguishing cHCC from iCCA (Table 2). Using the coefficients derived from the LASSO logistic regression models in the training set, we then constructed a formula to calculate for each patient. The LASSO coefficient profiles of the selected blood features are shown in Figure 3. The blood signature score was based on the personalized levels of the 7 blood features, as listed in Supplementary Table 2. Restrictive cubic spline functions of the blood-cHCC scores in the training and validation sets showed that the blood-cHCC score presented linear profiles (Supplementary Figure 2). Using the ROC curve, we classified patients into a typecHCC^{low risk} group and a type-cHCC^{high risk} group with a blood

signature score of -0.535 as the cut-off value (Supplementary Figure 1A). Based on the results of the blood signatures and multivariate logistic regression, a nomogram for distinguishing cHCC and iCCA was established (Figure 4). Point assignments and differential scores for each variable in the nomogram models are presented in Supplementary Table 3. According to the nomogram for distinguishing between cHCC and iCCA, the blood signature made the largest contribution. The calibration curve of the prediction nomogram for the differential diagnosis of cHCC and iCCA presented a good agreement in training and validation sets (Figures 4B, C). The Harrell's concordance index (C-index) for the nomogram for distinguishing cHCC and iCCA was 0.796 (95% CI, 0.752-0.840) for the training set and 0.824 (95% CI, 0.761-0.887) for the validation set, as detailed in Supplementary Table 4. After obtaining risk scores were obtained from the nomogram, risk classification of the differential diagnosis nomogram was conducted by ROC curve analysis. The patients were classified into low- and high-risk groups according to the optimal cut-off score of 119 on the cHCC nomogram (Supplementary Figure 1B). The high-risk group had a noticeably increased possibility of cHCC in the training set and validation set (Figures 5E-H). In addition, we performed survival analysis based on the cHCC nomogram risk score, and the highrisk groups had a worse prognosis in terms of RFS (Supplementary Figure 3). Hence, the nomogram could effectively distinguish between cHCC and iCCA before surgery but also predict prognosis after surgery to some extent.

DISCUSSION

Previous studies have classified cHCC and iCCA in the same category (7, 21), however, the prognosis of cHCC in comparison to iCCA remains controversial. Furthermore, treatment strategies for cHCC and iCCA differ. A previous study demonstrated that the molecular biology features of cHCC are more similar to those of hepatocellular carcinoma (HCC) than of iCCA, therefore, multitargeted inhibitors, including lenvatinib, regorafenib, and cabozantinib, may have potential for benefit in cHCC due to frequent alterations in RTK/Ras/PI3-kinase pathways (22). Moreover, liver transplantation might also bring potential survival benefits to patients with cHCC (23, 24). However, due to the current controversy over the value of liver transplantation for iCCA and the lack of indications for liver transplantation that meet the characteristics of the disease, liver transplantation has not been recommended as a routine treatment for iCCA. Since iCCA often metastasizes to distant sites in the early stage of the disease, which seriously affects long-term survival after transplantation, most centers in the West hold a conservative attitude towards the treatment of liver transplantation for iCCA (25). Curative liver resection is an important treatment for two types of resectable tumors. For resectable tumor, if we can distinguish the pathological type of the tumor before surgery, we can perform a comprehensive assessment to choose a wider surgical margin, anatomic liver resection. we could choose individualized treatment for each patient's condition especially for unresectable patients or





TABLE 2 | Logistic regression models of variables associated with distinguish combined hepatocellular cholangiocarcinoma (cHCC) from intrahepatic cholangiocarcinoma (iCCA) before surgery.

Variable	Univariate regression model			Multivariate regression model		
	Odds ratio	95% CI	P value	Odds ratio	95% CI	P value
Age (≥55 vs. <55 years)	0.530	0.348-0.805	0.003	0.568	0.366-0.882	0.012
Sex (female vs. male)	0.301	0.186-0.488	<0.001	0.354	0.215-0.582	<0.001
Diabetes (yes vs. no)	0.887	0.482-1.631	0.700			
Portal hypertension (present vs. absent)	2.020	1.204-3.389	0.008	1.816	1.066-3.095	0.028
Biliary duct stones (yes vs. no)	0.206	0.080-0.531	0.001	0.274	0.103-0.729	0.010
Maximum tumor size (>5 vs. ≤5cm)	0.900	0.593-1.365	0.620			
Tumor number (multiple vs. single)	0.792	0.501-1.251	0.317			
Macroscopic vascular invasion (yes vs. no)	0.746	0.475-1.174	0.206			

cHCC, combined hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; Cl, confidence interval. Bold indicates statistically significant difference.



FIGURE 3 | Blood-cHCC score models selection using the least absolute shrinkage and selection operator (LASSO) binary logistic regression model in the training set **(A)**. LASSO coefficient profiles of the seven selected blood signatures for combined hepatocellular cholangiocarcinoma (cHCC). A dashed vertical line is drawn at the value (logy=-3.3) chosen by 10-fold cross-validation. Vertical line was shown at the value selected using cross-validation, where the optimum lambda gave rise to seven features with nonzero coefficients **(B)**. Partial likelihood deviance for the LASSO coefficient profiles. The partial likelihood deviance (binomial deviance) curve was presented versus log (lambda). A light dashed vertical line stands for the minimum partial likelihood deviance. A dashed vertical line stands for the partial likelihood deviance at the value (logy=-3.3).

patients who could not guarantee the R0 margin of surgery, which is in line with the current concept of precision liver cancer surgery (26). cHCC is associated with high risk of recurrence following surgical resection as compared with iCCA. Closely post-operative monitoring is highly recommended for cHCC patients. Simultaneously, it could aid clinicians in explaining the illness for patient counseling. For unresectable iCCA, chemotherapy with gemcitabine, platinum compounds, and fluoropyrimidines is the main treatment choice. A recent multicenter study reported that postoperative chemotherapy with gemcitabine prolonged the Frontiers in Oncology | www.frontiersin.org



FIGURE 4 | Differential diagnosis nomograms for distinguishing combined hepatocellular cholangiocarcinoma (cHCC) and intrahepatic cholangiocarcinoma (iCCA) and the calibration plot (A). The nomogram maps the distinguishing ability of cHCC and iCCA on a scale of 0 to 200. For each covariate, a vertical line is drawn upwards and the corresponding points are noted. This is repeated for each covariate, ending with a total point that corresponds to the differential diagnosis axes to seek the probability of cHCC at the bottom of the nomogram. The C-index value for the nomogram distinguishing cHCC from iCCA was 0.796 (95% CI, 0.752–0.840). The calibration curve for distinguishing cHCC and iCCA in the training set (B) and in the validation set (C). Ideal line (blue), estimated probabilities correspond to the actual observed; apparent line (red), prediction capability of the model obtained after bootstrap correction.

 \odot

Α



High risk

Low risk

Not aHDD GHDD





43

Low rea.

Net oHCC

FIGURE 5 | The decision curves of the nomograms for distinguishing combined hepatocellular cholangiocarcinoma (CHCC) from intrahepatic cholangiocarcinoma (iCCA) in the training and validation sets. The Y-axis represents the net benefit. The X-axis shows the threshold probability. The horizontal solid black line represents the hypothesis that no patients experienced presence of cHCC, and the solid gray line represents the hypothesis that all patients met the endpoint (**A**, **B**). Clinical impact curves of the nomogram for distinguishing cHCC from iCCA in the training and validation set (**C**, **D**). At different threshold probabilities within a given population, the number of high-risk patients and the number of high-risk patients with the outcome are shown. Discriminatory power of the nomograms for cHCC status with bar charts. Risk classification of the differential diagnosis nomogram conducted by the Receiver operating characteristic (ROC) curve analysis, and the performance in distinguishing the cHCC from iCCA in the training and validation set (**E–H**).

survival time of patients at high risk of recurrence and metastasis (27). However, systemic therapy or chemotherapy is not the standard option for advanced and unresectable cHCC (28), and a large sample size is still needed to distinguish cHCC from iCCA, and determine the value of other treatments for cHCC, which reflected the significance and importance of our research.

To data, the gold standard for the preoperative diagnosis of liver tumors is fine needle aspiration biopsy, but for tumors without a biopsy path or with a small-diameter tumors, biopsies are usually not available before surgery. In addition, the pathological data obtained at the morphological, phenotypical, and molecular levels from these tiny fragments by fine-needle aspiration biopsy may be incomplete or only partially representative, especially for cHCC patients with two components. The real risk of seeding and the oncologic prognosis by inserting a needle into a liver tumor lesion are still unclear (29-31). In recent years, with the development of imaging technology, the role of liver biopsy in the diagnosis of primary liver cancer (PLC) has been challenged over time by the ability of imaging techniques to conjecture the histologic status (32, 33). Imaging techniques could also help clinicians to understand more information, such as vascular invasion and lymph node metastasis, and even determine the most appropriate operative method (34). However, the diagnosis of cHCC and the differentiation of cHCC from other PLCs based on imaging findings can be challenging because of the histologic diversity and complexity of cHCC components and the overlapping imaging characteristics with those of iCCA (35-37). Moreover, their clinical value is limited due to the lack of costly highresolution equipment and experienced radiologists especially in some developing areas. Therefore, a novel and noninvasive method is required to distinguish cHCC from iCCA before receiving various treatments.

To our knowledge, our research is the first large comprehensive comparison reported to date on the clinical characteristics and prognoses of cHCC and iCCA patients after surgery. Our study focused on distinguishing between cHCC and iCCA before liver resection using a simple predictive model that incorporated the clinical risk factors as well as laboratory blood indicators that could be used in daily clinical practice to accurately predict pathological information preoperatively, rather than being limited to the identification of clinicopathological risk factors in resected specimens.

In this study, we showed that the prognosis of cHCC was significantly worse than that of iCCA in both the training set and in the validation set. Differences in prognosis for iCCA and cHCC might be due to their distinct mechanisms of carcinogenesis and biological behaviors. It is increasingly believed that cHCC may originate from hepatic progenitor cells, which are intermediate stem cells capable of undergoing bidirectional differentiation into hepatocytes and bile duct epithelial cells (38, 39), causing cHCC to have significant heterogeneity and aggressive biological behavior. Coulouarn et al. determined that the occurrence of cHCC might be related to the microenvironment remodeling and the activation of TGF β and Wnt/ β -catenin were identified as the two major signaling pathways in cHCC (39). In addition, most patients with

cHCC have a background of hepatitis B cirrhosis, which easily leads to tumor recurrence. However, for iCCA, the possible causative risk factors include biliary diseases such as biliary duct stones, hepatobiliary flukes, primary sclerosing cholangitis, and biliary tract cysts (40). Although our study found that the cHCC and iCCA groups had significant differences in MVI and lymph node metastasis, which might be the basis for distinguishing between cHCC and iCCA, the above information was obtained only through postoperative pathological specimens. In our study, we found that liver function and coagulation function indicators in cHCC patients were higher than those in iCCA patients which might be related to the facts that cHCC patients usually are infected with hepatitis virus. The above might become a potential blood predictor to distinguish cHCC from iCCA. Age (<55 years) and portal hypertension were positively related to cHCC, while biliary duct stones and female sex were positive factors in the iCCA differential nomogram. Our differential diagnosis nomogram demonstrated good agreement between predictions and observations in the training and validation sets. In addition, we found that the nomogram we established has better diagnostic performance than other clinical risk factors or blood signatures alone. With our nomogram, we can identify the cHCC patients who were previously misdiagnosed with iCCA. These patients could regain the chance to undergo liver transplantation or targeted therapy. Additionally, our nomogram might serve as a selection tool to assess neoadjuvant treatment for iCCA patients during randomized clinical trials in the future. Meaningfully, the Kaplan-Meier survival curves demonstrated that the nomograms could not only effectively distinguish between cHCC and iCCA regardless of individual values, but also successfully discriminate among different risk groups, thereby improving clinical decision making.

Although our research provided a new and simple method to distinguish between iCCA and cHCC, several limitations should be taken into consideration when interpreting our findings. Our study was conducted at a single-center study, and due to the characteristics of retrospective studies, there may be potential selection bias. The data for the training set and validation set were obtained from a single center, which might have hampered the identification of possibly important predictive factors. Moreover, although hepatitis virus infection is an important pathogenic factor in the carcinogenesis of PLC in China, however, in the West, hepatitis C virus infection and alcohol or metabolic factors are usually the causes of PLC. Whether this differential diagnosis nomogram is generalizable to patients in Western countries is still worth exploring, other western liver cancer centers are needed to recruit to build external validation.

CONCLUSION

In conclusion, the current study proves that patients with cHCC have a poorer prognosis than those with iCCA and that cHCC is a distinct tumor different from iCCA. Furthermore, we constructed and validated a nomogram that optimally differentiates cHCC from iCCA preoperatively by combining

other clinical risk factors identified by logistic regression and blood signatures selected by the LASSO algorithm.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The study was approved by ethics committee of Sichuan University West China hospital and informed consent was taken from all the patients.

AUTHOR CONTRIBUTIONS

Study concept and design: TW, WXW, and WTW. Acquisition of data: TW, SS, and JZ. Statistical analysis of data: TW and XY. Drafting of the manuscript: TW and WXW. Critical revision of the manuscript: TW, WXW, SS, and WTW. All authors contributed to the article and approved the submitted version.

REFERENCES

- Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. *J Hepatol* (2019) 71(1):104–14. doi: 10.1016/ j.jhep.2019.03.013
- Wang T, Kong J, Yang X, Shen S, Zhang M, Wang W. Clinical features of sarcomatoid change in patients with intrahepatic cholangiocarcinoma and prognosis after surgical liver resection: A Propensity Score Matching analysis. J Surg Oncol (2020) 121(3):524–37. doi: 10.1002/ jso.25815
- Holzner ML, Tabrizian P, Parvin-Nejad FP, Fei K, Gunasekaran G, Rocha C, et al. Resection of Mixed Hepatocellular-Cholangiocarcinoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma: A Western Center Experience. *Liver Transpl* (2020) 26(7):888–98. doi: 10.1002/lt.25786
- Yamashita YI, Aishima S, Nakao Y, Yoshizumi T, Nagano H, Kuroki T, et al. Clinicopathological characteristics of combined hepatocellular cholangiocarcinoma from the viewpoint of patient prognosis after hepatic resection: High rate of early recurrence and its predictors. *Hepatol Res* (2020) 50(7):863–70. doi: 10.1111/hepr.13507
- Lee JH, Chung GE, Yu SJ, Hwang SY, Kim JS, Kim HY, et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol (2011) 45(1):69–75. doi: 10.1097/ MCG.0b013e3181ce5dfa
- Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. *J Hepato Biliary Pancreatic Surg* (2006) 13 (6):537–42. doi: 10.1007/s00534-006-1117-1
- Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. *Int J Clin Pract* (2008) 62(8):1271–8. doi: 10.1111/ j.1742-1241.2007.01694.x
- Edge SB, Byrd DR, Carducci MA, Compton CC, Fritz A, Greene F. AJCC cancer staging manual. 7th ed. New York, NY: Springer (2010) p. 201–5.

FUNDING

This research was funded by the National Natural Science Foundation of China (No. 81770566) and the Department of Science and Technology of Sichuan Province (No. 19ZDYF1682).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020. 598433/full#supplementary-material

SUPPLEMENTARY FIGURE 1 | (A) Receiver operating characteristic (ROC) curve analysis of the blood signature for cHCC. The areas under the curve (AUCs) were 0.806. The optimal cut-off blood score was -0.535 (B) Receiver operating characteristic (ROC) curve analysis of the nomogram risk score for distinguishing cHCC. The areas under the curve (AUCs) were 0.799. The optimal cut-off the nomogram risk score was 119.

SUPPLEMENTARY FIGURE 2 | The restricted cubic spline of the blood-cHCC score in training and validation sets (A, B). The restricted cubic spline of the nomogram risk score for distinguishing cHCC in training and validation sets (C, D).

SUPPLEMENTARY FIGURE 3 | Kaplan–Meier analysis of recurrence-free survival and overall survival according to risk score based on nomogram. The number at risk refers to the number of patients who have not relapsed at the corresponding time point.

- Amin MB, Edge SB. AJCC cancer staging manual. 8th ed. New York, NY: Springer (2017) p. 288–92.
- Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM classification of malignant tumours. 8th ed. New York, NY: Wiley Blackwell (2017) 83–84.
- Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. *Jpn J Clin Oncol* (2003) 33(6):283–7. doi: 10.1093/jjco/ hyg056
- Zuo HQ, Yan LN, Zeng Y, Yang JY, Luo HZ, Liu JW, et al. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma. *Hepatobiliary Pancreatic Dis Int HBPD Int* (2007) 6 (2):161–5.
- Yin X, Zhang BH, Qiu SJ, Ren G, Zhou J, Chen XH, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. *Ann Surg Oncol* (2012) 19(9):2869–76. doi: 10.1245/s10434-012-2328-0
- 14. Panjala C, Senecal DL, Bridges MD, Kim GP, Nakhleh RE, Nguyen JH, et al. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma. *Am J Transplant* 10(5):1263–7. doi: 10.1111/j.1600-6143.2010.03062.x
- Gera S, Ettel M, Acosta-Gonzalez G, Xu R. Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma. World J Hepatol (2017) 9(6):300–9. doi: 10.4254/wjh.v9.i6.300
- Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. *Stat Med* (2007) 26(30):5512–28. doi: 10.1002/sim.3148
- 17. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw (2010) 33(1):1–22.
- Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol (2008) 26(8):1364–70. doi: 10.1200/jco.2007.12.9791
- Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making* (2006) 26(6):565–74. doi: 10.1177/ 0272989x06295361

- Kerr KF, Brown MD, Zhu K, Janes H. Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use. J Clin Oncol (2016) 34(21):2534–40. doi: 10.1200/jco.2015.65.5654
- Sobin LH, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours, 7th Edition. New York, NY: Wiley Blackwell (2009) p. 108–10.
- Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, Onodera C, et al. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. *J Pathol* (2019) 248(2):164–78. doi: 10.1002/path.5243
- 23. Sapisochin G, de Lope CR, Gastaca M, de Urbina JO, López-Andujar R, Palacios F, et al. Intrahepatic cholangiocarcinoma or mixed hepatocellularcholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. *Ann Surg* (2014) 259(5):944–52. doi: 10.1097/sla.00000000000494
- Lunsford KE, Court C, Seok Lee Y, Lu DS, Naini BV, Harlander-Locke MP, et al. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation. *Liver Transpl* (2018) 24(10):1384–97. doi: 10.1002/lt.25058
- Lee DD, Croome KP, Musto KR, Melendez J, Tranesh G, Nakhleh R, et al. Liver transplantation for intrahepatic cholangiocarcinoma. *Liver Transpl* (2018) 24(5):634–44. doi: 10.1002/lt.25052
- Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. *Lancet Oncol* (2015) 16(4):e173–80. doi: 10.1016/s1470-2045(14)71116-7
- Reames BN, Bagante F, Ejaz A, Spolverato G, Ruzzenente A, Weiss M, et al. Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. *HPB* (2017) 19(10):901–9. doi: 10.1016/j.hpb.2017.06.008
- Feng M, Pan Y, Kong R, Shu S. Therapy of Primary Liver Cancer. *Innovation* (N Y) (2020) 1(2):100032. doi: 10.1016/j.xinn.2020.100032
- Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, et al. Complications of radiofrequency coagulation of liver tumours. *Br J Surg* (2002) 89(10):1206–22. doi: 10.1046/j.1365-2168.2002.02168.x
- Yu J, Liang P, Yu XL, Cheng ZG, Han ZY, Dong BW. Needle track seeding after percutaneous microwave ablation of malignant liver tumors under ultrasound guidance: analysis of 14-year experience with 1462 patients at a single center. *Eur J Radiol* (2012) 81(10):2495–9. doi: 10.1016/j.ejrad.2011.10.019
- 31. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. *Gut* (2008) 57(11):1592–6. doi: 10.1136/gut.2008.149062
- Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, et al. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol (2019) 25(40):6041–52. doi: 10.3748/wjg.v25.i40.6041

- 33. Zhang HC, Zhu T, Hu RF, Wu L. Contrast-enhanced ultrasound imaging features and clinical characteristics of combined hepatocellular cholangiocarcinoma: comparison with hepatocellular carcinoma and cholangiocarcinoma. *Ultrasonography* (2020) 30(4):356–66. doi: 10.14366/ usg.19093
- 34. Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *Surg Today* (2006) 36(10):892–7. doi: 10.1007/s00595-006-3276-8
- 35. Wang Y, Yang Q, Li S, Luo R, Mao S, Shen J. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population. *Clin Radiol* (2019) 74(5):407.e1-4e10. doi: 10.1016/ j.crad.2019.01.016
- 36. Sammon J, Fischer S, Menezes R, Hosseini-Nik H, Lewis S, Taouli B, et al. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma. *Cancer Imaging* (2018) 18(1):8–8. doi: 10.1186/s40644-018-0142-z
- Sagrini E, Iavarone M, Stefanini F, Tovoli F, Vavassori S, Maggioni M, et al. Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. U Eur Gastroenterol J (2019) 7 (1):69–77. doi: 10.1177/2050640618815378
- Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma. J Gastroenterol Hepatol (2010) 25(9):1485-92. doi: 10.1111/j.1440-1746.2010.06430.x
- Coulouarn C, Cavard C, Rubbia-Brandt L, Audebourg A, Dumont F, Jacques S, et al. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFbeta signaling pathways. *Carcinogenesis* (2012) 33(9):1791-6. doi: 10.1093/carcin/ bgs208
- 40. Wang Q, Li J, Lei Z, Wu D, Si A, Wang K, et al. Prognosis of Intrahepatic Cholangiocarcinomas with HBV Infection is Better than Those with Hepatolithiasis After R0 Liver Resection: A Propensity Score Matching Analysis. Ann Surg Oncol (2017) 24(6):1579–87. doi: 10.1245/s10434-016-5751-9

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Wang, Wang, Zhang, Yang, Shen and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.